Sign In
Buy RGLS
$8.16
+0 (+0%)
At Close: Sep 24, 2025
Statistically significant increase in urinary polycystin 1(PC1) after treatment with RGLS8429 Urinary polycystin exhibits anticipated pharmacokinetics/pharmacodynamics (PK/PD) correlation in patients
SAN DIEGO , Sept. 13, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
08:00am, Tuesday, 05'th Sep 2023
SAN DIEGO, Sept. 5, 2023 /PRNewswire/ -- Regulus Therapeutics Inc.
Regulus Therapeutics Inc's Uncertain Future: Understanding the Barriers to Outperformance
12:06pm, Wednesday, 23'rd Aug 2023
Long-established in the Biotechnology industry, Regulus Therapeutics Inc ( RGLS , Financial) has enjoyed a stellar reputation. It has recently witnessed a surge of 13.27%, juxtaposed with a three-mont
Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023
08:00am, Wednesday, 23'rd Aug 2023
SAN DIEGO , Aug. 23, 2023 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (
Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates
04:05pm, Tuesday, 08'th Aug 2023
First patient dosed in second cohort of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) in Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429 R&D Day to discuss our ADPKD pr
Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
08:00am, Wednesday, 02'nd Aug 2023
SAN DIEGO , Aug. 2, 2023 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (
Regulus (RGLS) Surges on Enrollment Completion for RGLS8429
02:25pm, Friday, 14'th Apr 2023
Regulus (RGLS) surges as it completes enrollment in the first cohort to evaluate RGLS8429 for kidney disease.
Regulus Therapeutics, Inc. (RGLS) Q3 2022 Earnings Call Transcript
09:49pm, Thursday, 10'th Nov 2022
Regulus Therapeutics, Inc. (NASDAQ:RGLS ) Q3 2022 Earnings Conference Call November 10, 2022 5:00 PM ET Company Participants Crispina Calsada - CFO Jay Hagan - President, CEO & Director Denis Drygin -
Regulus (RGLS) Up on Top-Line Data from Kidney Disease Study
01:32pm, Tuesday, 13'th Sep 2022
Regulus Therapeutics (RGLS) reports positive top-line data from a phase I single-dose ascending study of its lead candidate RGLS8429 in autosomal dominant polycystic kidney disease.
Hot Penny Stocks to Know About Right Now? 3 to Watch
06:00am, Tuesday, 13'th Sep 2022
Here's what you need to know about trading penny stocks on September 13th The post Hot Penny Stocks to Know About Right Now? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Informa
Regulus Therapeutics to Participate in Upcoming Investor Conferences
04:05pm, Friday, 02'nd Sep 2022
SAN DIEGO , Sept. 2, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (th
Regulus Therapeutics, Inc. (RGLS) CEO Joseph Hagan on Q2 2022 Results - Earnings Call Transcript
06:51pm, Thursday, 11'th Aug 2022
Regulus Therapeutics, Inc. (NASDAQ:RGLS ) Q2 2022 Earnings Conference Call August 11, 2022 5:00 PM ET Company Participants Crispina Calsada - CFO Joseph Hagan - President & CEO Conference Call Partici
Top Penny Stocks to Buy Now? 3 to Watch in June 2022
05:04pm, Friday, 27'th May 2022
Can these penny stocks make gains next month? The post Top Penny Stocks to Buy Now?
Check These 3 Penny Stocks Out For Your Watchlist
07:35pm, Monday, 23'rd May 2022
Are these penny stocks on your watchlist right now? The post Check These 3 Penny Stocks Out For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
